Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Jennifer Segar
Assistant Professor, Medicine - (Clinical Scholar Track)
Medicine
Overview
Research
More
Collaboration
(24)
Carolyn Lane
Mutual work: 2 Grants
Collaboration Details
Todd Vanderah
Mutual work: 1 Publication
Collaboration Details
Denise Roe
Mutual work: 5 Publications
Collaboration Details
Mohab Ibrahim
Mutual work: 1 Publication
Collaboration Details
Sima Ehsani Chimeh
Mutual work: 6 Grants﹒4 Publications
Collaboration Details
Page 1 of 5
Previous page
Next page
Grants
(21)
A Phase 1, Multi-center, Open Label First-in-Human Study with ABBV-CLS-579 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors
Active
·
2023
·
$830.5K
·
External
Principal Investigator (PI)
oncology,
clinical trials,
cancer treatment,
drug development,
immunotherapy
Phase 3, Open-Label, Randomized Study of Datopotamab Deruxtecan with or without Durvalumab Versus Investigator's Choice of Therapy in Patients with Stage I-III Triple Negative Breast Cancer who have R
Active
·
2023
·
$5M / $709.8K
·
External
Principal Investigator (PI)
breast cancer,
immunotherapy,
clinical trials,
combination therapy,
precision medicine
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study of IO-202 in Combination with Pembrolizumab in Subjects with Advanced, Relapsed, or Refractory Solid Tumors
Active
·
2023
·
$3.5M / $391.4K
·
External
Principal Investigator (PI)
immunotherapy,
cancer,
clinical trial,
combination therapy,
solid tumors
Phase 1 Study of Intratumoral Administration of VAX014 in Subjects with Advanced Solid Tumors
Active
·
2023
·
$4.6M / $352.4K
·
External
Principal Investigator (PI)
cancer immunotherapy,
clinical trial,
tumor microenvironment,
intratumoral therapy,
solid tumors
An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of
Active
·
2023
·
$2.1M / $342.9K
·
External
Principal Investigator (PI)
cancer treatment,
drug combination,
efficacy,
safety
Page 1 of 5
Previous page
Next page
Publications
(15)
Recent
Oxylipins as Biomarkers for Aromatase Inhibitor-Induced Arthralgia AIA) in Breast Cancer Patients. Metabolites br br Martinez JA, Wertheim BC, Roe DJ, Taljanovic MS, Chow HS, Chew W, Ehsani S, Jiralerspong S, Segar J Chalasani P. 2023 Mar 20;13(3)452. doi: 10.3390/metabo13030452. PMID: 36984892; PMCID: PMC10052117
2023
“Real-world data on outcomes using taxane, trastuzumab, and pertuzumab THP) in patients with early stage HER2+ breast cancer
2023
Investigating keratinocyte growth factor hair serum for the prevention of chemotherapy-induced alopecia.
2022
The Impact of Hormone Receptor Testing on Breast Cancer Treatment in Dar es Salaam, Tanzania
2021
Clinicopathological and Molecular Characteristics of Pleoorphic Invasive Lobular Carcinoma
2020
Charging forward in locally advanced pancreatic cancer
2020
pancreatic cancer,
cancer treatment,
medical advances,
tumor progression,
therapy development
Diffuse tensor imaging of lower extremities: a novel MR imaging technique for chemotherapy-induced peripheral neuropathy
2020
medical imaging,
neuropathy,
chemotherapy,
lower extremities,
research techniques
Abstract P3-08-27: Imaging predictors for development of chemotherapy induced peripheral neuropathy
2020
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
2019
Elderly AML: A Five-Year Retrospective Review on Prognostic Features
2018
elderly aml,
prognostic features,
retrospective review,
five-year,
aml